瑞银发表研究报告指，预期次季及上半年内地医药器械股份的业绩将继续分化。展望下半年，预计设备企业的国内收入将自第三季起显著增长，因上半年恢复招标逐步转化为收入。体外诊断(IVD)方面，虽然部分试剂价格或于第三季触底，但用量影响或要到今年末才会消退。耗材方面，各品类分化的势态将延续至下半年，另外该行关注国家医疗保障局近期强调带量采购反内卷后续政策，可能是中长期催化剂。海外业务方面，该行认为除非中美关税争端再起，各板块应可维持稳定增长。 该行最新较看好联影医疗及威高股份。联影医疗2025至27年收入有强劲增长潜力，估值溢价合理，予目标价192元，评级“买入”。威高股份今年全年10%至15%的收入增长指引虽然面临下行风险，但其收入及盈利有所增长，股东回报持续改善，且估值合理，目标价8.2港元，亦予“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.